T
Ton Oude Ophius
Researcher at Beth Israel Deaconess Medical Center
Publications - 4
Citations - 48
Ton Oude Ophius is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Myocardial infarction & Tolerability. The author has an hindex of 2, co-authored 4 publications receiving 33 citations.
Papers
More filters
Journal ArticleDOI
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
C. Michael Gibson,Serge Korjian,Pierluigi Tricoci,Yazan Daaboul,John H. Alexander,Philippe Gabriel Steg,A. Michael Lincoff,John J.P. Kastelein,Roxana Mehran,Denise D'Andrea,Béla Merkely,Maciej Zarębiński,Ton Oude Ophius,Robert A. Harrington +13 more
TL;DR: The AEGIS-I trial will characterize the safety profile of CSL112, a reconstituted, infusible human apolipoprotein A-I, and will assess if administration to patients with a recent AMI is associated with a clinically significant alteration in either liver or kidney function when compared with placebo.
Journal ArticleDOI
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Giulia Magnani,Diego Ardissino,KyungAh Im,Andrzej Budaj,Robert F. Storey,P. Gabriel Steg,Deepak L. Bhatt,Marc Cohen,Ton Oude Ophius,Assen Goudev,Alexander Parkhomenko,Gabriel Kamensky,Dominick J. Angiolillo,Jose Lopez-Sendon,Per Johanson,Eugene Braunwald,Marc S. Sabatine,Marc P. Bonaca +17 more
TL;DR: Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction, identification of patients at lower bleeding risk is important in selecting patients as mentioned in this paper.
Journal ArticleDOI
The safety and tolerability of multiple dose administration of csl112, an intravenous formulation of plasma-derived apoa-i, among subjects with moderate renal impairment after acute myocardial infarction
C. Michael Gibson,Megan Yee,Yazan Daaboul,Serge Korjian,Ali Poyan Mehr,Mathieu Kerneis,Pierluigi Tricoci,John Alexander,John Kastelein,Roxana Mehran,Christoph Bode,Basil Lewis,Ravindra Mehta,Danielle Duffy,John Feaster,Majdi Halabi,Dominick J. Angiolillo,Daniel Duerschmied,Ton Oude Ophius,Bela Merkely +19 more
TL;DR: CSL112 is plasma-derived apolipoprotein A-I, currently in development for early reduction of cardiovascular risk after acute myocardial infarction (AMI), and the AEGIS-I trial demonstrated renal and hepatic safety and elevations in cholesterol efflux.
Journal Article
Abstract 10398: Vorapaxar in Patients With Diabetes and Prior MI: Findings From the TRA 2P - TIMI 50 Trial
Matthew A. Cavender,Benjamin M. Scirica,Marc P. Bonaca,João Morais,Ton Oude Ophius,Tony Dalby,Sabina A. Murphy,Eugene Braunwald,David A. Morrow +8 more
TL;DR: Patients with diabetes mellitus are at particularly high risk of recurrence of MI, and Vorapaxar reduces cardiovascular death, myocardial infarction, or stroke in patients with prior MI.